PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma

Primary Objectives: ● To assess the complete response (CR) rate at the end of therapy (EOT) with Brentuximab vedotin and pembrolizumab, doxorubicin and dacarbazine in subject with previously untreated stage II bulky mediastinal disease or advanced stage cHL. Secondary Objectives: * To assess the safety of BvP+AD * To assess the complete remission rate at interim PET (CR iPET) * To assess the overall response rate (ORR) * To assess the duration of response (DOR) * To assess the duration of complete response (DOCR) * To assess event-free survival (EFS) * To assess progression free survival (PFS) * To assess overall survival (OS)